A Phase II Trial of single agent CABOZANTINIB in patients with locally advanced or metastatic non-clear cell renal cell carcinoma post immunotherapy or who are unsuitable for immunotherapy (ANZUP 1802)
- Gurney, Howard (Primary Chief Investigator)
- Chapman, Nicola, (Research Coordinator)
- Cunningham, Jacob, (Research Coordinator)
- Butala, Radhika, (Research Coordinator)
Project: Other